BUMETANIDE IN AUTISM SPECTRUM DISORDER

• Autor(a) principal: Moreira, Lucas da Silva
• Data de Publicação: 2022
• Outros Autores: Aragão, Gislei Frota
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Arquivos de Ciências da Saúde da UNIPAR (Online)
• Texto Completo: https://revistas.unipar.br/index.php/saude/article/view/8774

Objectives: This study aimed to make a bibliographic update on the already published data on bumetanide, addressing the main information on its use in Autism Spectrum Disorder (ASD).  Methods: This was an integrative narrative review in which the following databases were used: Web of Science, MEDLINE, ScienceDirect, and Scielo. The descriptors used were: Autism Spectrum Disorder, Autistic Disorder and Bumetanide. It was considered only articles published in English and French. Original articles, randomized clinical trials, case reports, and review articles were included. Results: The results show that the use of bumetanide alters regions of the brain linked to the positive development of language, improvement of visual contact, improvement in social interactions, among others. Studies are also concerned about the safety and efficacy of bumetanide in ASD since several adverse effects have been reported. The most frequent were hypokalemia, polyuria, and loss of appetite. Conclusion: Bumetanide has proven as effective in improving some important symptoms in ASD, especially linked to language and social interaction, however, studies with larger groups of patients and with longer treatment and observation time are needed to confirm the efficacy and clarify the safety profile in use for people with ASD.